<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">ISHIYAMA, YUDAI</style></author><author><style face="normal" font="default" size="100%">KONDO, TSUNENORI</style></author><author><style face="normal" font="default" size="100%">NEMOTO, YUKI</style></author><author><style face="normal" font="default" size="100%">KOBARI, YUKI</style></author><author><style face="normal" font="default" size="100%">ISHIHARA, HIROKI</style></author><author><style face="normal" font="default" size="100%">TACHIBANA, HIDEKAZU</style></author><author><style face="normal" font="default" size="100%">YOSHIDA, KAZUHIKO</style></author><author><style face="normal" font="default" size="100%">HASHIMOTO, YASUNOBU</style></author><author><style face="normal" font="default" size="100%">TAKAGI, TOSHIO</style></author><author><style face="normal" font="default" size="100%">IIZUKA, JUNPEI</style></author><author><style face="normal" font="default" size="100%">TANABE, KAZUNARI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1607-1614</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14922</style></doi><volume><style face="normal" font="default" size="100%">41</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab. Patients and Methods: Sixty-five patients were retrospectively enrolled and classified as low (&lt;40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated. Results: In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group. Conclusion: PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab.</style></abstract></record></records></xml>